Tredje AP fonden reduced its stake in United Therapeutics Co. (NASDAQ:UTHR) by 66.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,060 shares of the biotechnology company’s stock after selling 8,040 shares during the quarter. Tredje AP fonden’s holdings in United Therapeutics were worth $476,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in UTHR. US Bancorp DE raised its position in United Therapeutics by 3.2% in the 2nd quarter. US Bancorp DE now owns 4,175 shares of the biotechnology company’s stock valued at $541,000 after buying an additional 128 shares during the last quarter. World Asset Management Inc raised its position in United Therapeutics by 3.1% in the 2nd quarter. World Asset Management Inc now owns 2,973 shares of the biotechnology company’s stock valued at $386,000 after buying an additional 88 shares during the last quarter. Pictet Asset Management Ltd. raised its position in United Therapeutics by 6.3% in the 2nd quarter. Pictet Asset Management Ltd. now owns 95,711 shares of the biotechnology company’s stock valued at $11,571,000 after buying an additional 5,700 shares during the last quarter. Canada Pension Plan Investment Board raised its position in United Therapeutics by 34.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 74,692 shares of the biotechnology company’s stock valued at $9,690,000 after buying an additional 19,190 shares during the last quarter. Finally, Arizona State Retirement System raised its position in United Therapeutics by 1.6% in the 2nd quarter. Arizona State Retirement System now owns 19,000 shares of the biotechnology company’s stock valued at $2,465,000 after buying an additional 300 shares during the last quarter. 99.94% of the stock is owned by institutional investors and hedge funds.

Shares of United Therapeutics Co. (NASDAQ:UTHR) opened at $136.21 on Friday. United Therapeutics Co. has a 12-month low of $112.01 and a 12-month high of $169.89. The stock has a market capitalization of $5,922.94, a price-to-earnings ratio of 12.09 and a beta of 1.42.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.01 by $2.26. United Therapeutics had a return on equity of 57.06% and a net margin of 62.02%. The firm had revenue of $445.50 million during the quarter, compared to analyst estimates of $426.43 million. During the same period last year, the firm posted $4.23 EPS. The business’s revenue was up 9.1% compared to the same quarter last year. analysts predict that United Therapeutics Co. will post 12.45 EPS for the current year.

A number of equities research analysts recently commented on the company. ValuEngine raised United Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 30th. BidaskClub raised United Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday. TheStreet lowered United Therapeutics from a “b-” rating to a “c” rating in a research report on Friday, September 29th. HC Wainwright reaffirmed a “hold” rating and set a $95.00 target price on shares of United Therapeutics in a research report on Thursday, October 26th. Finally, Cowen reaffirmed a “hold” rating and set a $129.00 target price on shares of United Therapeutics in a research report on Friday, October 27th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $136.10.

In other news, Director Christopher Causey sold 580 shares of the stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $122.00, for a total transaction of $70,760.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,258 shares of the stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $122.08, for a total value of $153,576.64. Following the transaction, the chief executive officer now owns 2,327 shares of the company’s stock, valued at approximately $284,080.16. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,668 shares of company stock valued at $2,755,406. Insiders own 7.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.watchlistnews.com/tredje-ap-fonden-has-476000-position-in-united-therapeutics-co-uthr/1755231.html.

United Therapeutics Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.